Clinical Trial Update: Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating total-body irradiation with fludarabine and alemtuzumab followed by stem cell transplant in patients with myeloproliferative d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndromes
• Myeloproliferative Disorders

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Fludarabine (Fludarabine)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Status: TERMINATED